Safety, Tolerability, and Activity of Mesenchymal Stem Cells versus Placebo in Multiple Sclerosis (MESEMS): A Phase II, Randomised, Double-Blind Crossover Trial

Bone marrow-derived MSC treatment was safe and well tolerated but did not show an effect on gadolinium-enhancing lesions, an MRI surrogate marker of acute inflammation, in patients with active forms of multiple sclerosis, at week 24.